-
Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy
•
China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase II clinical study for its IBI311, a recombinant anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in thyroid-associated ophthalmopathy (TAO). IBI311 is an IGF-1R-targeting monoclonal antibody independently developed by Innovent, marking a significant step in the…
-
Hygea Medtech Secures Series D Funding for Oncology Device Expansion
•
Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based in Beijing, has reportedly raised “hundreds of millions” of renminbi in a Series D financing round. This significant funding round was led by In Capital, with contributions from Banyan Pacific Capital, Huajin Capital, Qiandao Investment…
-
CTI Acquires Vectoring Pharmatech to Expand Pharmacy CMC Research
•
China-based Centre Testing International Group Co., Ltd (CTI), a leading third-party testing and qualification services provider, has announced the 100% acquisition of compatriot firm Vectoring Pharmatech Ltd. This strategic move is designed to enhance CTI’s business layout in the pharmacy CMC (Chemistry, Manufacturing, and Controls) research field. No financial details…
-
Shenzhen United Family Hospital Partners with GBA Medical Delegation
•
Shenzhen United Family Hospital has struck a partnership with a medical delegation from the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), aimed at accelerating high-quality healthcare development and medical exchanges in the region. This collaboration is a significant step towards enhancing the healthcare ecosystem in the GBA. Shenzhen United Family Hospital:…
-
Vincentage Raises RMB 100 Million for Innovative Drug Development
•
Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6 million) in its latest financing round. This significant funding will be used to accelerate clinical studies and regulatory filings for multiple innovative drugs, particularly oral small molecule GLP-1RA drugs, as well as to develop new…
-
Sequanta and Grandomics Collaborate on Ultra-High Throughput Sequencing Lab
•
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences Co., Ltd, a Beijing-based biotech specializing in applying bioinformatics, genomics, and cutting-edge internet technologies to clinical medicine and personal health, have signed a long-term collaboration agreement. The partnership aims to integrate short-read sequencing and long-read…
-
Luzhu Biotech Files for IPO in Hong Kong, Sponsored by CICC
•
Beijing Luzhu Biotechnology Co., Ltd, a leading human vaccine and therapeutic biologics maker, has made another initial public offering (IPO) filing with the Hong Kong Stock Exchange, sponsored by CICC. This marks the company’s second attempt at going public on the bourse, following the failure of its first IPO attempt…
-
China’s NRDL Update: New Drugs Available for Online Procurement
•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) drug procurement platform has released a notice stating that drugs newly added to the 2022 edition of the National Reimbursement Drug List (NRDL) are now available for online procurement by hospitals. The 2022 NRDL update, which was completed in mid-January 2023, includes 111 newly…
-
Mindray Launches First Wireless Handheld Ultrasound System, TE Air
•
China-based medical device firm Mindray (SHE: 300760) has announced the market launch of the firm’s first wireless handheld ultrasound system, branded TE Air. This innovative device represents a historic breakthrough in image quality, integrating professional-level imaging into a compact and lightweight wireless system for ease of use in various medical…
-
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
•
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced a licensing agreement with US firm Cullinan Oncology, Inc. The deal grants Cullinan exclusive rights to develop and commercialize HBM7008 in the United States (including the District of Columbia and Puerto Rico). This…
-
Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment in a Phase I clinical study for its tetravalent influenza virus split vaccine. This marks a significant step in the development of a vaccine designed to provide broader protection against influenza, particularly for individuals aged…
-
Jiangsu Recbio Completes First Tranche Enrollment for Shingles Vaccine REC610
•
China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of subject enrollment in a clinical study for its novel adjuvanted recombinant shingles vaccine, REC610. This milestone marks a significant step in the development of a vaccine designed to provide enhanced protection against shingles, particularly for…
-
Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine
•
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and first subject enrollment in a Phase I clinical study for its 20-valent pneumonia vaccine. This marks a significant step in the development of a vaccine designed to provide broader protection against pneumonia. Vaccine Development and…
-
Gracell Biotechnologies Gains IND Approval for GC012F in China
•
Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) for its chimeric antigen receptor (CAR) T cell candidate GC012F. The dual BCMA/CD19-targeted therapy is set to be assessed in treating relapsed/refractory multiple myeloma (r/r MM), marking a significant step in the development…
-
China’s Ministries Release Plan for Urban Medical Group Pilots
•
A group of ministries led by the National Health Commission (NHC), including the National Development and Reform Commission (NDRC), Ministry of Finance, Ministry of Human Resources and Social Security, National Administration of Traditional Chinese Medicine, and National Bureau of Disease Control and Prevention, have jointly released a work plan for…
-
ThinmedTech Partners with West China Hospital for CKD Digital Therapy
•
ThinmedTech, a chronic disease clinical management solution provider based in Chongqing, has struck a partnership with West China Hospital. The collaboration aims to work together on medical research and product transformation in the area of “chronic kidney disease (CKD) sodium restriction digital therapy.” This partnership marks a significant step in…
-
RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study
•
China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products Administration (NMPA) to initiate an open, single-center Phase Ib/II clinical study. The study will assess the safety, efficacy, and pharmacokinetics of its antibody-drug conjugate (ADC) candidate RC48 (disitamab vedotin) combined with Hengrui pharmamceuticals’ pyrotinib, a…
-
Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine SCB-2019 (CpG 1018/Alum) in Zhejiang. This recombinant protein vaccine is recommended by the national second dosage (fourth shot) booster immunization plan and is suitable for use in the elderly, immune-compromised individuals, and populations with complications.…
-
Hengrui Pharmaceuticals Licenses SHR2554 to Treeline Biosciences
•
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced a licensing agreement with US-based Treeline Biosciences, Inc. The deal grants Treeline exclusive development, manufacturing, and commercialization rights to the pipeline candidate SHR2554 in markets outside of the Greater China area. This strategic partnership aims to expand the global reach of SHR2554,…
-
CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus Pharmaceuticals Inc. The deal pertains to CSPC’s anti-nectin-4 antibody drug conjugate (ADC) SYS6002. Under the terms of the agreement, Corbus obtains development and commercialization rights to SYS6002 in the United States, EU, United Kingdom, Canada,…
